Skeletal muscle loss during neoadjuvant chemotherapy predicts poor prognosis in patients with breast cancer.

ABSTRACT:

Background

The skeletal muscle index (SMI), which is calculated as the ratio of skeletal muscle area at the third lumbar vertebral level divided by height squared, has been considered a prognostic factor in patients with breast cancer. However, the prognostic impact of changes in SMI during treatment remains unclear. This study aimed to evaluate the influence of SMI changes in patients with breast cancer undergoing neoadjuvant chemotherapy (NAC).

Methods

We reviewed patients with breast cancer who underwent NAC and subsequent surgery for breast cancer between 2010 and 2017. The rate of SMI change during NAC was calculated, and the association between SMI changes and prognosis was retrospectively analyzed.

Results

In total, 141 patients were evaluated. 48 (34.0%), 53 (

SUBMITTER: Amitani M 

PROVIDER: S-EPMC8962250 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature